Abstract
Measurements of serum triiodothyronine (T3) concentrations were made in 46 patients who had thyroid ablation for thyroid cancer and who were receiving T3 three times a day as suppressive treatment. In all patients thyrotropin (TSH) suppression was confirmed by the inhibition of TSH response to thyrotropin releasing hormone (TRH). The suppressive dose of T3 varied from 40 to 100 μg/day (mean ± SD 72.39 + 13.07 μg/day). Related to body weight the dose varied from 0.95 to 1.35 μg/kg/day (mean ± SD 1.13 ± 0.13 μg/kg/day). In ten hospitalized patients serum T3 levels were measured at hourly intervals from 08:00 to 23:00. Before the first dose of T3, serum T3 levels were 153 ± 43 ng/100 ml; after T3 the levels increased promptly reaching after 4 h a peak of 264 ± 90 ng/100 ml. Afterwards T3 levels showed asimilar peak after each dose: 262 ± 77 and 266 ± 78 ng/100 ml, slightly decreasing in the intervals between the doses: 227 ± 63 and 255 ± 69 ng/100 ml. After the last peak T3 levels showed a slow decline during the night. TSH response to TRH was completely inhibited both at 08:00 and at 16:00. In 36 outpatients T3 levels were measured twice a day and T3 levels were found similar to the ones of the first group. In these patients also TSH response to TRH evaluated at 08:00 was completely inhibited. No important side effect was noted in both groups of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Busnardo B., Vangelista R., Girelli M.E., Bui F., Lazzi C. TSH levels and TRH as a guide to the replacement treatment of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 42: 901, 1976.
Busnardo B., Girelli M.E., Cimitan M., Casara D., Bui F., Lazzi C., Argenti G. Relationships between metastases of differentiated thyroid carcinoma and serum thyrotropin levels. J. Clin. Endocrinol. Metab. 44: 1193, 1977.
Hoffman D.P., Surks M.I., Oppenheimer J.H., Weitzman E.D. Response to thyrotropin releasing hormone: an objective criterion of the adequacy of thyrotropin suppression therapy. J. Clin. Endocrinol. Metab. 44: 892, 1977.
Lamberg B.A., Rantanen M., Saarinen P. Choosing thyroxine dose after treatment of thyroid cancer. Lancet 2: 1290, 1977.
Evered D., Young E.T., Ormston B.J., Menzies R., Smith P.A., Hall R. Treatment of hypothyroidism: a repraisal of thyroxine therapy. Br. Med. J. 3: 131, 1973.
Maeda M., Kuzuya N., Masuyama Y., Imai Y., Ikeda H., Uchimura H., Matsuzaki F., Kumagai L.F., Nagataki S. Changes in serum triiodothyronine, thyroxine and thyrotropin during treatment with thyroxine in severe primary hypothyroidism. J. Clin. Endocrinol. Metab. 43: 10, 1976.
Jackson I.M.D., Cobb W.E. Why does anyone still use desiccated thyroid USP? Am. J. Med. 64: 284, 1978.
Saberi M., Utiger R.D. Serum thyroid hormone and thyrotropin concentrations during thyroxine and triiodothyronine therapy. J. Clin. Endocrinol. Metab. 39: 923, 1974.
Stock J.M., Surks M.I., Oppenheimer J.H. Replacement dosage of L-thyroxine in hypothyroidism: a re-evaluation. N.Engl. J. Med. 290: 529, 1974.
Ambrosino N., Ceccarelli C., Mammoli C., Martino E., Mazzanti F., Pinchera B., Baschieri L. Tiroxina, triiodotironina e tireotropina circolanti in corso di terapia sostitutiva con vari preparati tiroidei. In: Tronchetti F., Menchini-Fabris G.F. (Eds.), Atti delle Giornate Endocrinologiche Pisane. Pacini Pisa, 1976, p. 481.
Sthal T.J., Shapiro B. Use of human thyrotropin radioimmunoassay in the management of patients with thyroid carcinoma. J. Nucl. Biol. Med. All. Sci. 14: 900, 1973.
Mornex R., Huges B., Perrot L. Methods of follow-up for treated thyroid carcinoma. Ann. Radiol. 20: 856, 1977.
Hershman J.M., Edwards C.L. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for131I treatment of thyroid carcinoma. J. Clin. Endocrinol. Metab. 34: 814, 1972.
Tubiana M., Charbord P., Cukersztein W., Sarrazun D., Fontaine F., Parmantier C. The role of radiotherapy and radioactive iodine in the treatment of thyroid cancer metastases. Ann. Radiol. 20: 801, 1977.
Cotton G.E., Gorman C.A., Mayberry W.E. Suppression of thyrotropin (hTSH) in serum of patients with myxedema of varying etiology treated with thyroid hormones. Engl. J. Med. 285: 529, 1971.
Busnardo B., Vangelista R., Girelli M.E., Lazzi C., Bui F. Serum levels of TSH and T3 and TRH stimulation in the follow-up of patients with thyroid carcinoma. Endocrinol Exp. 8: 22, 1974.
Hays M.T. Absorption of triiodothyronine in man. J. Clin. Endocrinol. Metab. 36: 1050, 1973.
Chopra I.J., Solomon D.H., Teco G.N.C. Thyroxine: just a prohormone or a hormone too? J. Clin. Endocrinol. Metab. 36: 1050, 1973.
Pinchera B., Sardano G., Capiferri R., Vaudagna G., Simonetti S. Free thyroid hormones in thyroid disease and effect of thyroid replacement therapy: observation by frequent sampling. In: Ekins R., Faglia G., Pennisi F., Pinchera B. (Eds.), Free thyroid hormones. Excerpta Medica, Amsterdam, 1979, p. 208.
Patel Y.C., Alford F.P., Burger H.G. The 24 hour plasma thyrotropin profile. Clin. Sci. Mol. Med. 43: 71, 1972.
Vanhaelst L., Van Cauter E., Degaute J.P., Golstein J. Orcadian variations of serum thyrotropin levels in man. J. Clin. Endocrinol. Metab. 35: 479, 1972.
Weeke J. Circadian variation of the serum thyrotropin levels in normal subjects. Scand. J. Clin. Invest. 31: 337, 1973.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Busnardo, B., Girelli, M.E., Bui, F. et al. Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment. J Endocrinol Invest 3, 353–356 (1980). https://doi.org/10.1007/BF03349370
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349370